RxDoctor Payments Data

J Watts, DO

Neurology · Albertville, ALNPI 1205889581

Payments from drug & device makers

$14,042in general payments, 2019–2025

Across 813 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$2K
  • UCB, Inc.$2K
  • AbbVie$2K
  • SK Life Science, Inc.$941
  • Acorda Therapeutics, Inc$657
  • Lundbeck LLC$627
  • plus $7K from 44 others

What the payments were for

  • Speaking & faculty fees$2492%
  • Food & beverage$13,76998%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$14,042 in reported general payments places this provider in the 65th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$168,205
Medicare patients
422
Services billed
1,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5062$1,688,288
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5060$717,680
NuplazidPimavanserin Tartrate13$63,636
NeuproRotigotine53$57,736
QuliptaAtogepant31$39,418
Aimovig AutoinjectorErenumab-Aooe30$35,151
BriviactBrivaracetam19$34,994
Nurtec OdtRimegepant Sulfate20$34,320
XcopriCenobamate27$32,039
Emgality PenGalcanezumab-Gnlm32$24,421
Lacosamide196$21,475
FycompaPerampanel13$19,513
NuedextaDextromethorphan Hbr/Quinidine13$18,418
AptiomEslicarbazepine Acetate11$13,528
Divalproex Sodium ErDivalproex Sodium195$8,715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$98$717,68060 claims
UCB, Inc.Neupro, Briviact$1,722$92,73072 claims
Acadia Pharmaceuticals IncNuplazid$22$63,63613 claims
PfizerNurtec Odt, Eliquis$360$42,21334 claims
AbbVieQulipta$1,550$39,41831 claims
SK Life Science, Inc.Xcopri$941$32,03927 claims
Eisai Inc.Fycompa$204$19,51313 claims
Avanir Pharmaceuticals, Inc.Nuedexta$347$18,41813 claims
Sunovion Pharmaceuticals Inc.Aptiom$185$13,52811 claims
Arbor Pharmaceuticals, Inc.Horizant$49$6,96713 claims
Upsher-smith Laboratories LLCTopiramate$131$1,942297 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$96$99116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 255 neurology providers in Alabama.

Other neurology in Albertville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →